169 related articles for article (PubMed ID: 37204338)
21. More than just risk for Alzheimer's disease: APOE ε4's impact on the aging brain.
Palmer JM; Huentelman M; Ryan L
Trends Neurosci; 2023 Sep; 46(9):750-763. PubMed ID: 37460334
[TBL] [Abstract][Full Text] [Related]
22. Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program.
Walsh T; Duff L; Riviere ME; Tariot PN; Doak K; Smith M; Borowsky B; Lopez Lopez C; Arratia PC; Liu F; Scholten I; Gordon D; Arbuckle J; Graf A; Quinn M; Ricart J; Langbaum JB
J Prev Alzheimers Dis; 2023; 10(3):453-463. PubMed ID: 37357285
[TBL] [Abstract][Full Text] [Related]
23. The Role of Apolipoprotein E ε4 in Early and Late Mild Cognitive Impairment.
Luo Y; Tan L; Therriault J; Zhang H; Gao Y;
Eur Neurol; 2021; 84(6):472-480. PubMed ID: 34340229
[TBL] [Abstract][Full Text] [Related]
24. The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status.
Ouk M; Wu CY; Rabin JS; Jackson A; Edwards JD; Ramirez J; Masellis M; Swartz RH; Herrmann N; Lanctôt KL; Black SE; Swardfager W
Alzheimers Res Ther; 2021 Feb; 13(1):43. PubMed ID: 33573702
[TBL] [Abstract][Full Text] [Related]
25. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
Wattmo C; Blennow K; Hansson O
BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein E moderates the association between non-APOE polygenic risk score for Alzheimer's disease and aging on preclinical cognitive function.
Xu Y; Sun Z; Jonaitis E; Deming Y; Lu Q; Johnson SC; Engelman CD
Alzheimers Dement; 2024 Feb; 20(2):1063-1075. PubMed ID: 37858606
[TBL] [Abstract][Full Text] [Related]
27. Impact of APOE ε4 genotype on initial cognitive symptoms differs for Alzheimer's and Lewy body neuropathology.
Pillai JA; Bena J; Bonner-Jackson A; Leverenz JB
Alzheimers Res Ther; 2021 Jan; 13(1):31. PubMed ID: 33485373
[TBL] [Abstract][Full Text] [Related]
28. The roles of apolipoprotein E ε4 on neuropathology and neuroinflammation in patients with Alzheimer's disease.
He M; Lian T; Guo P; Zhang W; Zhang Y; Huang Y; Liu G; Guan H; Li J; Luo D; Zhang W; Zhang W; Qi J; Yue H; Wang X; Zhang W
CNS Neurosci Ther; 2024 Mar; 30(3):e14440. PubMed ID: 37697966
[TBL] [Abstract][Full Text] [Related]
29. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
Saddiki H; Fayosse A; Cognat E; Sabia S; Engelborghs S; Wallon D; Alexopoulos P; Blennow K; Zetterberg H; Parnetti L; Zerr I; Hermann P; Gabelle A; Boada M; Orellana A; de Rojas I; Lilamand M; Bjerke M; Van Broeckhoven C; Farotti L; Salvadori N; Diehl-Schmid J; Grimmer T; Hourregue C; Dugravot A; Nicolas G; Laplanche JL; Lehmann S; Bouaziz-Amar E; ; Hugon J; Tzourio C; Singh-Manoux A; Paquet C; Dumurgier J
PLoS Med; 2020 Aug; 17(8):e1003289. PubMed ID: 32817639
[TBL] [Abstract][Full Text] [Related]
30. Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease.
Mielke MM; Leoutsakos JM; Tschanz JT; Green RC; Tripodis Y; Corcoran CD; Norton MC; Lyketsos CG
J Alzheimers Dis; 2011; 26(1):127-34. PubMed ID: 21593560
[TBL] [Abstract][Full Text] [Related]
31. The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study.
Gharbi-Meliani A; Dugravot A; Sabia S; Regy M; Fayosse A; Schnitzler A; Kivimäki M; Singh-Manoux A; Dumurgier J
Alzheimers Res Ther; 2021 Jan; 13(1):5. PubMed ID: 33397450
[TBL] [Abstract][Full Text] [Related]
32. Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment.
Insel PS; Hansson O; Mattsson-Carlgren N
JAMA Neurol; 2021 Feb; 78(2):229-235. PubMed ID: 33044487
[TBL] [Abstract][Full Text] [Related]
33. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease.
Craft S; Teri L; Edland SD; Kukull WA; Schellenberg G; McCormick WC; Bowen JD; Larson EB
Neurology; 1998 Jul; 51(1):149-53. PubMed ID: 9674794
[TBL] [Abstract][Full Text] [Related]
34. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
Lozupone M; Imbimbo BP; Balducci C; Lo Vecchio F; Bisceglia P; Latino RR; Leone M; Dibello V; Solfrizzi V; Greco A; Daniele A; Watling M; Seripa D; Panza F
Alzheimers Dement; 2023 Jan; 19(1):353-368. PubMed ID: 35900209
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.
Risner ME; Saunders AM; Altman JF; Ormandy GC; Craft S; Foley IM; Zvartau-Hind ME; Hosford DA; Roses AD;
Pharmacogenomics J; 2006; 6(4):246-54. PubMed ID: 16446752
[TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology.
Baum L; Chen L; Ng HK; Pang CP
Microsc Res Tech; 2000 Aug; 50(4):278-81. PubMed ID: 10936880
[TBL] [Abstract][Full Text] [Related]
37. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease.
Konijnenberg E; Tijms BM; Gobom J; Dobricic V; Bos I; Vos S; Tsolaki M; Verhey F; Popp J; Martinez-Lage P; Vandenberghe R; Lleó A; Frölich L; Lovestone S; Streffer J; Bertram L; Blennow K; Teunissen CE; Veerhuis R; Smit AB; Scheltens P; Zetterberg H; Visser PJ
Alzheimers Res Ther; 2020 May; 12(1):65. PubMed ID: 32460813
[TBL] [Abstract][Full Text] [Related]
38. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
Wang S; Zhang J; Pan T;
Neurosci Lett; 2018 Oct; 685():109-113. PubMed ID: 30144541
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein E ε4 allele impairs cortical activity in healthy aging and Alzheimer's disease.
Pedroso RV; Fraga FJ; Nascimento CMC; Pott-Junior H; Cominetti MR
Behav Brain Res; 2022 Feb; 420():113700. PubMed ID: 34871705
[TBL] [Abstract][Full Text] [Related]
40. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
